ES2525317T3 - Producción recombinante de inhibidores de la fusión antivirales peptídicos - Google Patents

Producción recombinante de inhibidores de la fusión antivirales peptídicos Download PDF

Info

Publication number
ES2525317T3
ES2525317T3 ES02740652.9T ES02740652T ES2525317T3 ES 2525317 T3 ES2525317 T3 ES 2525317T3 ES 02740652 T ES02740652 T ES 02740652T ES 2525317 T3 ES2525317 T3 ES 2525317T3
Authority
ES
Spain
Prior art keywords
peptide
fusion peptide
host cell
length
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02740652.9T
Other languages
English (en)
Inventor
Eva Hoess
Thomas Meier
Gabriele Pestlin
Friedrich Popp
Klaus Reichert
Rainer Schmuck
Bernd Schneidinger
Christoph Seidel
Wilhelm Tischer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2525317T3 publication Critical patent/ES2525317T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un proceso para la producción de un péptido antifusogénico como un péptido de fusión de una longitud de aproximadamente 14 a aproximadamente 70 aminoácidos en una célula huésped procariótica, que se caracteriza porque, en condiciones tal es que se formen cuerpos de inclusión de dicho péptido de fusión, a) en dicha célula huésped se expresa un ácido nucleico que codifica dicho péptido de fusión que consta de dicho péptido antifusogénico de una longitud de aproximadamente 10 a aproximadamente 50 aminoácidos unido por el extremo N-terminal a un péptido adicional de una longitud de alrededor de 4 a aproximadamente 30 aminoácidos; b) dicha célula huésped se hace crecer en cultivo; c) se forman dichos cuerpos de inclusión, se recuperan y se solubilizan; d) se aisla dicho péptido de fusión, y dicho péptido de fusión es representado por la Id. de Sec. Nº: 2, 11 o 12 y dicho péptido antifusogénico consiste en una secuencia de aminoácidos de Id. de Sec. Nº: 7, 9 o 10, o de un fragmento de la misma.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12

Claims (1)

  1. imagen1
ES02740652.9T 2001-06-15 2002-05-27 Producción recombinante de inhibidores de la fusión antivirales peptídicos Expired - Lifetime ES2525317T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01114497 2001-06-15
EP01114497 2001-06-15
PCT/EP2002/005782 WO2002103026A2 (en) 2001-06-15 2002-05-27 Method for the recombinant production of peptidic antiviral fusion inhibitors, and acetylation of gb41 fragments

Publications (1)

Publication Number Publication Date
ES2525317T3 true ES2525317T3 (es) 2014-12-22

Family

ID=8177732

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02740652.9T Expired - Lifetime ES2525317T3 (es) 2001-06-15 2002-05-27 Producción recombinante de inhibidores de la fusión antivirales peptídicos

Country Status (10)

Country Link
US (2) US6858410B2 (es)
EP (1) EP1402050B1 (es)
JP (1) JP4267444B2 (es)
KR (2) KR100614714B1 (es)
CN (1) CN1255548C (es)
AU (1) AU2002314111A1 (es)
CA (1) CA2450548C (es)
ES (1) ES2525317T3 (es)
MX (1) MXPA03011453A (es)
WO (1) WO2002103026A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2525317T3 (es) 2001-06-15 2014-12-22 F. Hoffmann-La Roche Ag Producción recombinante de inhibidores de la fusión antivirales peptídicos
CA2443365C (en) * 2002-11-19 2010-01-12 F. Hoffmann-La Roche Ag Methods for the recombinant production of antifusogenic peptides
US7744897B2 (en) 2003-12-23 2010-06-29 Dillon Susan B Human immunodeficiency virus gp41 mimetibody polypeptides
US20090088365A1 (en) * 2005-11-02 2009-04-02 Roberto Mariani Biosynthetic Polypeptide Fusion Inhibitors
GB0608368D0 (en) * 2006-04-28 2006-06-07 Isis Innovation Process for making Oligopeptides
TW200817438A (en) * 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
CL2008000707A1 (es) * 2007-03-13 2008-09-22 Hoffmann La Roche Conjugado de polipeptidos antifusogenicos y polipeptidos derivados de la cabeza globular del factor del complemento c1q; composicion farmaceutica que lo comprende; su uso para tratar infecciones viricas; y metodo de produccion.
EP2858661B1 (en) * 2011-12-29 2020-04-22 Dana-Farber Cancer Institute, Inc. Stabilized antiviral fusion helices
WO2014012090A1 (en) * 2012-07-13 2014-01-16 The Broad Institute, Inc. Molecular sleds comprising a positively-charged amino acid sequence and a molecular cargo and uses thereof
JP7105696B2 (ja) 2016-02-29 2022-07-25 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 感染症を治療するステープル化細胞内ターゲティング抗微生物ペプチド
WO2019018499A2 (en) 2017-07-19 2019-01-24 Dana-Farber Cancer Institute, Inc. ANTIMICROBIAL PEPTIDES STABILIZED FOR THE TREATMENT OF ANTIBIOTIC-RESISTANT BACTERIAL INFECTIONS

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9667A (en) * 1853-04-12 Washiug-machine
US123039A (en) * 1872-01-23 Improvement in canal-boats
DE3034045A1 (de) 1980-09-10 1982-04-22 Boehringer Mannheim Gmbh, 6800 Mannheim Endoproteinase-lys-c aus bakterien, verfahren zu ihrer gewinnung und verwendung
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4511503A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US5453363A (en) 1985-10-23 1995-09-26 Boehringer Mannheim Gmbh Process for the activation of t-PA or Ing after genetic expression in prokaryotes
CU22222A1 (es) * 1989-08-03 1995-01-31 Cigb Procedimiento para la expresion de proteinas heterologicas producidas de forma fusionada en escherichia coli, su uso, vectores de expresion y cepas recombinantes
US5595887A (en) 1990-07-16 1997-01-21 Bionebraska, Inc. Purification directed cloning of peptides using carbonic anhydrase as the affinity binding segment
US5656456A (en) 1992-07-13 1997-08-12 Bionebraska, Inc. Chemical method for selective modification of the N- and/or C-terminal amino acid α-carbon reactive group of a recombinant polypeptide or a portion thereof
ATE225801T1 (de) 1992-07-13 2002-10-15 Bionebraska Inc Verfahren zur modifizierung rekombinanter polypeptide
DE69326069T2 (de) 1992-07-20 2000-03-23 Univ Durham Zusammensetzungen die die hiv replikation inhibieren
CA2142306A1 (en) * 1992-08-21 1994-03-03 Robert E.W. Hancock Cationic peptides and method for production
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US6017536A (en) 1993-06-07 2000-01-25 Trimeris, Inc. Simian immunodeficiency virus peptides with antifusogenic and antiviral activities
US5512459A (en) 1993-07-20 1996-04-30 Bionebraska, Inc. Enzymatic method for modification or recombinant polypeptides
US5648244A (en) * 1993-09-27 1997-07-15 President And Fellows Of Harvard College Production, purification, cleavage and use of fusion peptides
DE4405810A1 (de) * 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
KR100571215B1 (ko) * 1995-06-07 2006-10-24 트라이머리스 인코퍼레이티드 복합적인치료요법을이용한hiv와다른바이러스감염의치료
US6846905B2 (en) * 1997-08-15 2005-01-25 Abbott Laboratories Antigen constructs useful in the detection and differentiation of antibodies to HIV
BR9909018A (pt) 1998-03-23 2001-10-16 Trimeris Inc Processo para a sìntese de um peptìdeo, conjunto de fragmentos de peptìdeo, e, peptìdeo
US6656906B1 (en) 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6258782B1 (en) 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
ES2263278T3 (es) * 1998-07-10 2006-12-01 Scios Inc. Metodo para producir un peptido con un pl por encima de 8 o por debajo de 5.
WO2000031279A2 (en) 1998-11-20 2000-06-02 Micrologix Biotech Inc. Producing antimicrobial cationic peptides as fusion proteins
EP1149115A4 (en) * 1999-01-08 2005-11-02 Panacos Pharmaceuticals Inc TECHNIQUES FOR ELICITATION OF NEUTRALIZING ANTIBODIES TARGETING HIV-1 gp41
EP1264840B1 (en) 1999-05-17 2009-09-23 ConjuChem Biotechnologies Inc. Long lasting fusion peptide inhibitors of viral infection
EP1237912B1 (en) * 1999-12-16 2007-12-12 Whitehead Institute For Biomedical Research Five-helix protein
ES2525317T3 (es) 2001-06-15 2014-12-22 F. Hoffmann-La Roche Ag Producción recombinante de inhibidores de la fusión antivirales peptídicos

Also Published As

Publication number Publication date
KR100614714B1 (ko) 2006-08-21
EP1402050A2 (en) 2004-03-31
JP4267444B2 (ja) 2009-05-27
KR20060035814A (ko) 2006-04-26
US20030104581A1 (en) 2003-06-05
AU2002314111A1 (en) 2003-01-02
CN1516738A (zh) 2004-07-28
CA2450548C (en) 2012-05-01
JP2004529660A (ja) 2004-09-30
CN1255548C (zh) 2006-05-10
CA2450548A1 (en) 2002-12-27
US7348423B2 (en) 2008-03-25
WO2002103026A3 (en) 2003-11-20
US20050058659A1 (en) 2005-03-17
KR20040010705A (ko) 2004-01-31
WO2002103026A2 (en) 2002-12-27
US6858410B2 (en) 2005-02-22
KR100694919B1 (ko) 2007-03-14
MXPA03011453A (es) 2004-04-05
EP1402050B1 (en) 2014-10-29

Similar Documents

Publication Publication Date Title
ES2525317T3 (es) Producción recombinante de inhibidores de la fusión antivirales peptídicos
CA2443365A1 (en) Methods for the recombinant production of antifusogenic peptides
RU2017123283A (ru) Партнеры по слиянию для получения пептидов
JP2017536835A5 (es)
CO6251278A2 (es) Metodo para la produccion de conjugados del factor de crecimiento similar a la insulina -1 y polietilenglicol
IL210455A (en) A polypeptide for reducing mammalian signaling 13il, and using a polypeptide to produce a drug for up-regulating gene expression 2ra13-il in mammals
JP2004532033A5 (es)
DE60227064D1 (de) Von rna polymerasen abstammende polypeptide und ihre verwendungen
ES2531372T3 (es) Enzimas de procesamiento fusionadas a marcadores de proteínas básicas
DE602005009738D1 (de) Verfahren zur herstellung und sekretion modifizierter peptide
ES2531402T3 (es) Colagenasa de fusión a la que se une una marca de afinidad, y método para producir la misma
DE60041257D1 (de) Cdc27-homologe aus arabidopsis thaliana
PE20020857A1 (es) Proteinas de fusion cuya parte del n-terminal es un derivado de hirudina para la produccion de proteinas recombinantes a traves de la secresion por levaduras
DE602005025141D1 (de) In Zellen eindringende Peptide als Träger für Moleküle
JP2020529221A5 (es)
RU2009115688A (ru) Иммуногенные гибридные полипептиды против ожирения и композиция вакцин против ожирения, содержащая эти полипептиды
EP0528686B8 (en) Process for producing peptides
KR970065554A (ko) 프로세싱 효소를 사용한 키메라 단백질의 절단 방법
AR016208A1 (es) Fragmento aislado de acidos nucleicos que codifica toda o una porcion substancial de una proteina de transporte de sacarosa, gen quimerico, celula huespedtransformada, polipeptido de dicha proteina, metodo para alterar el nivel de expresion de dicha proteina en una celula huesped, metodo para obtene
Brown et al. Purification, partial characterization and peptide sequences of vitellogenin from a reptile, the tuatara (Sphenodon punctatus)
Gohara et al. Phosphorylation of vimentin head domain inhibits interaction with the carboxyl-terminal end of α-helical rod domain studied by surface plasmon resonance measurements
PE20001068A1 (es) Produccion de analogos de tripsinogeno recombinante solubles
Tereshin et al. Optimized method for the recombinant production of a sea anemone’s peptide
WO2012048856A1 (en) Proinsulin with helper sequence
BR9709205A (pt) Polipeptìdeos processados com arividade de il-16, processos para a sua produção e seu uso